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Background: Some Chinese herbs contain several kinds of phytoestrogens, and these herbs are commonly
prescribed in Taiwan. Phytoestrogens may influence the effects of estrogen in females, although their activities are
weak. This study aims to identify the risk and analyze the prescription profile of commonly used phytoestrogenic
herbs in Taiwan.
Methods: The study analyzed women who had been prescribed phytoestrogenic herbs including coumestrol,
genistein and/or daidzein between 1997 and 2007 in a fixed cohort taken from all female beneficiaries from the
National Health Insurance Research Database of Taiwan. The prescription frequencies, cumulated dosages, and
primary indications were listed.
Results: A total of 462,861 women were included in the study, of whom ~47.0% had used phytoestrogenic herbs
at least once during the study period. A total of 6,270,813 prescriptions were recorded, and more than 20% of
these contained phytoestrogens. The most commonly prescribed herb and formula were Puerariae Radix and Ge
gen tang (Pueraria Decoction), respectively. Most of the prescriptions were issued for diseases of the respiratory
system, followed by symptoms, signs, and ill-defined conditions and diseases of the musculoskeletal system and
connective tissue.
Conclusion: This study shows that women who sought medical treatment from Chinese medicine doctors for relief
of respiratory discomfort had a high possibility of exposure to phytoestrogenic herbs. Safety issues related to the
female endocrine system should be a priority for future research.Background
Phytoestrogens may interact with the estrogen receptors
that mediate endocrine homeostasis, causing damage to
reproductive health, especially at developing life stages
[1-3]. Although the phytoestrogenic activities are weaker
than those of human endogenous estrogens, the con-
sumption of phytoestrogens may have clinically significant* Correspondence: kareny@ms10.hinet.net
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reproduction in any medium, provided the orconsequences [4]. Coumestrol, genistein and daidzein
are strong phytoestrogens that are found in many foods
and Chinese medicine (CM) product [5-7]. There is a
concern among CM doctors and CM users about incon-
clusive safety results from various in vitro and in vivo
models in estrogenic studies, especially for patients taking
Chinese herbal products (CHPs) containing coumestrol,
genistein, and/or daidzein (CGD-CHPs).
CM has been an important part of healthcare in Taiwan
for hundreds of years, and CHPs have been regularly
reimbursed by the National Health Insurance (NHI) sys-
tem since 1995 [8]. All CHPs are fully reimbursed underThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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provides a platform for understanding the utilization
of CGD-CHPs.
This study aims to analyze random samples from the
NHI database to determine the risk and prescription
profile of CGD-CHPs among female beneficiaries in
Taiwan between January 1997 and December 2007.Methods
Study subjects
The source population for this study was women who
had been prescribed CGD-CHPs between 1997 and 2007
in a randomly sampled cohort from all NHI female
beneficiaries in Taiwan. This research included females
from the randomly sampled cohort aged 1 to 99 years as
the study subjects, and age was calculated by subtracting
the subject’s birthday from the 1st of July of each year.
The NHI system provides universal health insurance
coverage, and covered more than 97% of the Taiwanese
population in 2002 [9]. Consequently, data from the
NHI system are widely used by researchers in various
fields [10]. Both CM and Western medicine doctors
must follow a standard diagnostic procedure using the
International Classification of Diseases, 9th Revision,
Clinical Modification (ICD-9-CM) coding system for
claiming reimbursement. Because the NHI system of
Taiwan does not reimburse the use of CM for inpatient
services, we only investigated the use of CM for out-
patient services. The NHI reimbursement data files
were transformed into a research database entitled the
National Health Insurance Research Database (NHIRD)
that was maintained by the National Health Research
Institutes. In the NHIRD, all the identification informa-
tion is encrypted but the medical records files are
retained, including information from 1997 to 2007 on
medical care facilities and specialties, drugs and/or
treatment regimens (dosages, dosage frequency and
prescription duration), patient sex and date of birth,
date of visit, and three major diagnoses coded in the
ICD-9-CM format. The NHIRD contains a one-
million cohort systematically and randomly selected
from the 23 million people in the NHI database who
were ever insured under the NHI system in 2005. For
each subject, we collected all records of CHPs during
1997 to 2007 as a female cohort. We considered the
first diagnosis to be the major diagnosis on the
records for outpatient department visits, which were
coded in ICD-9-CM and then lumped together into
different broader disease categories, e.g., lists of ICD-
9-CM codes 710–739 were classified as diseases of
the musculoskeletal system and connective tissue,
while ICD-9-CM codes 460–519 were classified as
diseases of the respiratory system.List of licensed CHPs
The list of reimbursed CHPs was obtained from the Bur-
eau of the NHI website. The corresponding drug infor-
mation about specific mixtures or names was obtained
from the Committee on Chinese Medicine and Phar-
macy (CCMP) website, and included the proportions of
each constituent, date, approval period as a drug, code
and manufacturers’ names. The CCMP list shows that
10,413 CHPs were licensed during the study period, of
which 10,309 CHPs were covered by the NHI system.
All CHPs with the same CCMP standard formula were
classified under the same category, regardless of slight
variations among products of different pharmaceutical
companies [11]. For example, there are 62 approved
licenses for the formula Ge gen tang containing coumes-
trol, genistein and/or daidzein.
Selection of herbs and estimation of cumulative doses
The CGD-CHPs examined in this study included Psora-
leae Fructus, Puerariae Radix, Sojae Semen Praepara-
tum, Sophorae Flavescentis Radix and Sophorae Flos. We
examined all of the CHPs licensed by the CCMP be-
tween 1997 and 2007, including single herbs and herbal
formulae, to determine whether they included CGD-
CHPs. The original weight of each herb was then calcu-
lated according to the contents manufactured by the in-
dividual pharmaceutical company registered for each
licence and approved by the CCMP.
Statistical analysis
The data were analyzed by descriptive statistics, in-
cluding the decomposition of the coumestrol, genistein
and daidzein contents of the licensed and prescribed
CHPs, CGD-CHP prescription rates stratified by age,
the medians (with 10th and 90th percentiles) of the
cumulative doses of coumestrol, genistein and daidzein,
population distribution of patients who had been po-
tentially exposed to coumestrol, genistein and daidzein
under various dosages, the frequencies of the disease
categories prescribed with CGD-CHPs, the most fre-
quently prescribed herbal formulae containing CGD-
CHPs, and so on. All of these analyses were performed
using the SAS software package (version 9.1; SAS Inc.,
Cary, NC, USA).
Results
Between 1 January 1997 and 31 December 2007, 721
(7%) CGD-CHPs were identified among the 10,309
licensed CHPs, of which the top three CGD-CHPs were
Puerariae Radix (4.9%), Sophorae Flavescentis Radix
(0.7%), and Sojae Semen Praeparatum (0.7%). A total of
6,270,813 cases of prescribed and reimbursed CGD-
CHPs were recorded (Table 1). Among all the CGD-
CHPs, Puerariae Radix was the most frequently
Table 1 Distribution frequencies of licensed and prescribed CHPs containing phytoestrogens* based on a one-million
patient random sample (1997–2007) from the NHI system of Taiwan















Total no. (%) licensed CHPs 10,309 (100) 342,440 (100) 6,270,813 (100) -
Licensed CGD-CHPs 721 (7.0) 217,897 (63.6) 1,389,244 (22.2) -
Puerariae Fructus 60 (0.6) 13,761 (4.0) 35245 (0.6) 5.9 (2.0-34.0) Genistein, daidzein and
biochanin A, coumestrol
Puerariae Radix 505 (4.9) 182,899 (53.4) 986,110 (15.7) 10.8 (1.7-57.6) Puerarin, daidzin, genistin,
daidzein and genistein,
coumestrol
Sojae Semen Praeparatum 74 (0.7) 86,273 (25.2) 323,413 (5.2) 4.2 (0.6-17.5) Genistein, genistin, daidzein,
daidzin, glycitein and glycitin,
coumestrol
Sophorae Flavescentis Radix 75 (0.7) 63,511 (18.5) 180,720 (2.9) 4.9 (1.5-15.0) Daidzein, genistein and
formononetin
Sophorae Flos 38 (0.4) 8,853 (2.6) 25,871 (0.4) 12.6 (2.0-48.0) Genistin, genistein
*Phytoestrogens mainly contained coumestrol, genistein and/or daidzein.
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CM practitioners in Taiwan. The co-existence of more
than two major active phytoestrogens was identified
in licensed and prescribed CGD-CHPs. Genistein-
containing herbal prescriptions comprised 80% of the
prescribed CGD-CHPs.
Among the one-million randomly sampled cohorts,
462,861 women between the ages of 1 and 99 years
were included in the analysis. From 1997 to 2007,
342,440 (74.0%) of the women used CHPs on at least
one occasion, of whom 217,897 (63.6%) were treated
with prescriptions containing coumestrol, genistein
and/or daidzein. The CGD-CHPs-exposed population
included many women of reproductive age (Table 2).
When calculating individuals’ exposure, most patients
were exposed to low cumulative doses (less than 50 g)Table 2 Prescription frequencies of CHPs containing phytoest
five major Chinese herbs stratified by age, based on a one-m
system of Taiwan
Chinese herbal products ≤ 9 10-19 20-29
Total licensed CHPs 252,268 594,059 1,069,122
Licensed CGD-CHPs. 62,140 135,716 220,967
Average dosage per woman-year (g) a
Puerariae Fructus 10.2 18.0 14.5
Puerariae Radix 25.8 27.8 29.2
Sojae Semen Praeparatum 8.6 9.5 9.6
Sophorae Flavescentis Radix 9.0 10.5 10.9
Sophorae Flos 15.9 24.6 27.3
a Converted back to the original weight.
*Phytoestrogens mainly contained coumestrol, genistein and/or daidzein.of CGD-CHPs, although ~5% of the patients were pre-
scribed with Puerariae Radix at cumulative doses
above 57.6 g (Table 1). Given that the random sample
in this cohort accounted for approximately 5% of the
Taiwanese population, it can be inferred that about
180,000 women were exposed to such high cumulative
doses of Puerariae Radix.
The major disease categories with CGD-CHPs pre-
scription included respiratory diseases (556,464 visits)
and symptoms, signs, and ill-defined conditions (263,742
visits), followed by musculoskeletal system and connect-
ive tissue diseases (152,471 visits) and digestive diseases
(105,448 visits) (Table 3). CGD-CHPs were usually pre-
scribed in the form of herbal formulae, especially Ge gen
tang (Pueraria Decoction, containing Puerariae Radix)
and Yin qiao san (Lonicera and Forsythia Powder,rogena* and cumulative average original weights of the
illion patient random sample (1997–2007) from the NHI
Age
30-39 40-49 50-59 60-69 70-79 ≥ 80
1,368,722 1,332,924 818,922 496,445 268,747 69,604
307,731 301,586 186,354 108,348 54,060 12,342
15.9 17.9 21.3 21.0 22.0 21.3
33.7 37.0 39.0 41.4 41.5 40.4
11.0 11.4 11.4 12.4 11.3 10.5
10.9 10.7 10.5 10.8 10.6 11.4
33.5 35.5 37.3 36.4 49.9 34.3
Table 3 Frequency distribution of the top 10 disease categories for prescribing CHPs containing phytoestrogens*
Major disease category ICD-9-CM code range Number of visits %
Total - 1,389,244 100
Diseases of the respiratory system 460–519 556,464 40.1
Symptoms, signs, and ill-defined conditions 780–799 263,742 19.0
Diseases of the musculoskeletal system and connective tissue 710–739 152,471 11.0
Diseases of the digestive system 520–579 105,448 7.6
Diseases of the skin and subcutaneous tissue 680–709 95,315 6.9
Diseases of the genitourinary system 580–629 65,837 4.7
Injury and poisoning 800–999 39,366 2.8
Diseases of the nervous system and sense organs 320–389 35,585 2.6
Diseases of the circulatory system 390–459 22,932 1.7
Endocrine, nutritional and metabolic diseases, and immunity disorders 240-279 14,889 1.1
The population was women aged 0–99 years among the one-million patient NHIRD cohort.
*Phytoestrogens mainly contained coumestrol, genistein and/or daidzein.
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CGD-CHPs were prescribed for a treatment period of
less than 30 days, and the most common dosage fre-
quency was three times per day. Furthermore, most CM
female users consumed no more than 30 g of CDG-
CHPs containing daidzein and genistein.
Discussion
To the best of our knowledge, this is the first study to
document the use of CHPs containing phytoestrogens inTable 4 Commonly prescribed single herbs and herbal formu
Drug name
Total herbal prescription
Herbal prescription containing coumestrol, genistein and/or daidzein






Herbal formulae (English name)
Ge gen tang Pueraria Decoction
Yin qiao san Lonicera and Forsythia Powder
Chai ge jie ji tang Bupleurum and Pueraria Flesh-Resolving Decocti
Xiao feng san Wind-Dispersing Powder
Dang gui nian tong tang Chinese Angelica Pain-Assuaging Decoction
Shi shen tang Ten Spirits Decoction
Ge gen qin lian tang Pueraria, Scutellaria, and Coptis Decoction
Shen su yin Ginseng and Perilla Beverage
Qing shu yi qi tang Summerheat-Clearing Qi-Boosting Decoction
San zhong kui jian tang Swelling-Dispersing Hardness-Breaking Decoction
a CGD-CHPs refers to Chinese herbal products containing coumestrol, genistein anda random national-level sample containing all detailed
medical records. We focused on active ingredients that
could be considered to be potent phytoestrogens, namely
coumestrol, genistein and daidzein, in women who sought
medical treatment from CM doctors. Among the licensed
CHPs in Taiwan, 7% contained coumestrol, genistein and/
or daidzein. However, these products comprised 22.2% of
the CM prescriptions consumed by about half of the
female population in Taiwan during the 11-year
study period. Diseases of the respiratory system werelae of CGD-CHPs a
Herbs with phytoestrogens Prescriptions %
6,270,813 100
1,389,244 22.2
Puerariae Radix 223,313 3.6
Puerariae Fructus 24,040 0.4
Sophorae Flavescentis Radix 17,865 0.3
Sophorae Flos 11,811 0.2
Sojae Semen Praeparatum 5,132 0.1
Puerariae Radix 315,781 5.0
Sojae Semen Praeparatum 307,692 4.9
on Puerariae Radix 115,629 1.8
Sophorae Flavescentis Radix 85,502 1.4
Puerariae Radix Sophorae Flavescentis Radix 81,063 1.3
Puerariae Radix 75,271 1.2
Puerariae Radix 60,686 1.0
Puerariae Radix 34,848 0.6
Puerariae Radix 32,338 0.5
Puerariae Radix 27,071 0.4
/or daidzein.
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CHPs were prescribed, constituting 40% of CM
visits. This finding indicates that female CM users in
Taiwan may not have expected to be exposed to
phytoestrogenic herbs when they used CM therapies
to manage the discomfort of a sore throat, cough,
and runny nose. Exposure to Puerariae Radix was
the most extensive, and nearly 5% of female CM
users consumed cumulative doses of Puerariae Radix
above 60 g.
In addition, the present data show that the major con-
sumers of CDG-CHPs were aged between 20 and 49
years. Little is known about phytoestrogenic herbs and
their potential interactions with the endocrine system,
and therefore special attention should be drawn to the
herbal formulae containing phytoestrogenic herbs, espe-
cially the prescriptions for female patients of reproduct-
ive age suffering from respiratory diseases.
According to CM theory [12], Puerariae Radix can
dispel exterior cold syndrome of the excessive type
and alleviate muscle aches in the neck and back
caused by cold constriction. Previous in vitro studies
have indicated that Puerariae Radix is rich in cou-
mestrol, genistein and daidzein as soya, which may
reduce cancer cell viability and induce apoptosis
[13,14]. And, epidemiological studies also suggested
that exposure to relatively high concentrations of phy-
toestrogens early in life may decrease the prevalence
of cancer development later in life [15,16]. CM doctors
should observe the potential effects of phytoestrogenic
herbs on consumers’ endocrine systems proactively at the
early stage to avoid any consequences of chronic CM
therapy administration.
Our study has two limitations. First, the NHI system
only reimburses CHPs, and decoctions are not included
and cannot be generalized for their usage. In addition,
this study did not include Chinese herbal remedies and
health foods containing herbs that can be directly pur-
chased from CM pharmacies. Thus, the frequency of
phytoestrogenic herb consumption might be underesti-
mated. Because the NHIRD collects all prescription in-
formation prospectively, we can rule out the possibility
of a recall bias concerning intake dosages and different
types of herbal prescriptions. In addition, as the rate of
insured individuals in the NHIRD has consistently
exceeded 96% since 1997, we can exclude the possibil-
ity of a selection bias. Therefore, the estimated preva-
lence rate presented here is close to the true use of
CGD-CHPs by female beneficiaries in Taiwan. Another
limitation is that only herbs containing coumestrol,
genistein and/or daidzein were included in the study,
meaning that there must be caution in generalizing
these findings to use of phytoestrogens among the fe-
male population.Conclusion
This study shows that women who sought medical treat-
ment from CM doctors for relief of respiratory discomfort
had a high possibility of exposure to phytoestrogenic
herbs. Safety issues related to the female endocrine system
should be a priority for future research.
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